Lilly Innovent Biologics alliance could reach $9 billion, focusing on drug development in China.
Author: PharmaSignal News Desk
PharmaSignal Take This week’s events highlight the increased scrutiny on pricing practices and the continued push for innovation in the pharma industry. The FDA’s regulatory actions and the strategic deals being made underscore the importance of execution readiness and platform scalability in this rapidly evolving landscape. In this week’s PharmaSignal Weekly Brief – Global Pharma Roundup, we see a strong focus on regulatory actions, strategic deals, and pipeline developments. M&A and Strategic Deals AstraZeneca’s $15B investment in China’s drug development signals a strategic shift towards high-growth markets and underlines the importance of geographic optionality. Read more → Halozyme’s $400M acquisition…
Bayer Asundexian Stroke Prevention shows a 26% risk reduction in Phase 3 trial, boosting its commercial outlook.
Express Scripts settlement with FTC includes changes to insulin pricing practices and reshoring of rebate aggregator.
Lilly earnings guidance indicates 2025 sales of Zepbound and Mounjaro exceeding $36 billion, surpassing Wall Street expectations.
Amgen inflammatory drug faces regulatory scrutiny as the company refuses FDA’s withdrawal request, impacting its market strategy.
FDA PreCheck program opens to pharmaceutical facilities aligning with national priorities, impacting AstraZeneca and Acadia drugs.
PharmaSignal Take This week’s events signal a continued trend of strategic acquisitions and partnerships, alongside regulatory advancements and setbacks. Notably, AstraZeneca’s massive investment in China’s drug development and Halozyme’s acquisition of a biotech startup stress-test the assumption of integration risk and platform scalability. These decisions will have significant implications for post-close activities and portfolio strategy. The PharmaSignal Weekly Brief – Global Pharma Roundup this week highlights themes of M&A activity, regulatory acceleration, and pipeline risk. M&A and Strategic Deals AstraZeneca’s $15B investment in China’s drug development signals a strategic move to capitalize on the growing Asian market. The deal’s success…
AstraZeneca China investment of $15B aims to enhance drug research and development capabilities.
Tenpoint FDA approval marks a significant step for its presbyopia eye drop, supported by $235 million in funding.